Literature DB >> 9914949

Cytokines in autoimmune disorders.

M Feldmann1, F M Brennan, R Maini.   

Abstract

Cytokines are important protein mediators of immunity, inflammation, cell proliferation, differentiation, fibrosis, etc. (Oppenheim and Saklatvala, 1993). As these are the major biological processes underlying autoimmunity, it is not surprising that there is now convincing evidence that cytokines have an important role in the pathogenesis of autoimmunity (Brennan and Feldmann, 1996; Feldmann et al., 1996). There has been much progress since we first highlighted the role of cytokines such as IFN gamma in autoimmunity in the early 1980s (Bottazzo et al., 1983). The number of cytokines molecularly cloned has increased greatly, and the biochemical and structural basis of their action are partly understood, as cytokine genes and that of their receptors have been cloned. Knowledge of cytokine signalling is rapidly expanding (see Chapter XIII). In medical terms, clear evidence of the importance of cytokines in autoimmunity is demonstrated by therapeutic advances. Thus it is possible to dramatically improve patients with rheumatoid arthritis and Crohn's disease by blocking TNF alpha, and a new target for therapy, TNF alpha, has thus been validated for both these diseases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9914949     DOI: 10.3109/08830189809084493

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  28 in total

1.  TNF-alpha and chronic fatigue syndrome.

Authors:  R B Moss; A Mercandetti; A Vojdani
Journal:  J Clin Immunol       Date:  1999-09       Impact factor: 8.317

2.  Preferential type 1 chemokine receptors and cytokine production of CD28- T cells in ankylosing spondylitis.

Authors:  C Duftner; C Dejaco; W Kullich; A Klauser; C Goldberger; A Falkenbach; M Schirmer
Journal:  Ann Rheum Dis       Date:  2005-10-11       Impact factor: 19.103

Review 3.  Analysing the effect of novel therapies on cytokine expression in experimental arthritis.

Authors:  Richard O Williams; Julia J Inglis; Egle Simelyte; Gabriel Criado; Percy F Sumariwalla
Journal:  Int J Exp Pathol       Date:  2005-10       Impact factor: 1.925

4.  Adaptive Immunity Against Staphylococcus aureus.

Authors:  Hatice Karauzum; Sandip K Datta
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

Review 5.  Cytokine-based therapy in psoriasis.

Authors:  Anupam Mitra; Robyn S Fallen; Hermenio Cavalcante Lima
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

6.  Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis.

Authors:  K Bendtzen; P R Hansen; K Rieneck
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

7.  Inhibition of TNF alpha during maturation of dendritic cells results in the development of semi-mature cells: a potential mechanism for the beneficial effects of TNF alpha blockade in rheumatoid arthritis.

Authors:  A W T van Lieshout; P Barrera; R L Smeets; G J Pesman; P L C M van Riel; W B van den Berg; T R D J Radstake
Journal:  Ann Rheum Dis       Date:  2004-07-15       Impact factor: 19.103

8.  Targeting IL-23: insights into the pathogenesis and the treatment of psoriasis.

Authors:  Hermenio Cavalcante Lima; Alexandra Boer Kimball
Journal:  Indian J Dermatol       Date:  2010 Apr-Jun       Impact factor: 1.494

9.  Involvement of interferon-gamma genetic variants and intercellular adhesion molecule-1 in onset and progression of generalized vitiligo.

Authors:  Mitesh Dwivedi; Naresh C Laddha; Kriti Shah; Bela J Shah; Rasheedunnisa Begum
Journal:  J Interferon Cytokine Res       Date:  2013-06-18       Impact factor: 2.607

10.  Biologics: target-specific treatment of systemic and cutaneous autoimmune diseases.

Authors:  Siba P Raychaudhuri; Smriti K Raychaudhuri
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.